PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

DGAP-News: MorphoSys AG / Key word(s): Study

New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in

Early Alzheimer's Disease now Underway (news with additional features)

2018-06-12 / 22:01

The issuer is solely responsible for the content of this announcement.

Planegg/Munich, Germany, June 12, 2018

*New Phase 3 Clinical Trials by MorphoSys's Partner with Gantenerumab in

Early Alzheimer's Disease now Underway*

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)

announced today that the first patient has been enrolled in a new phase 3

trial of gantenerumab in patients with early Alzheimer's disease.

Gantenerumab is a monoclonal antibody directed against amyloid-beta

generated by MorphoSys using its proprietary HuCAL antibody technology.

Roche is fully responsible for the clinical development of gantenerumab.

MorphoSys is entitled to receive potential success-based regulatory

milestone payments related to gantenerumab and royalties on net sales.

Expected to enroll approximately 1,520 patients in up to 350 study centers

in 31 countries worldwide, the pivotal program consists of the two phase 3

studies named GRADUATE-1 and GRADUATE-2. The two multicenter, randomized,

double-blind, placebo-controlled trials will enroll up to 760 patients each,

to assess the efficacy and safety of gantenerumab in patients with early

(prodromal to mild) Alzheimer's disease. All participants need to show

evidence of beta-amyloid pathology. Patients will receive placebo or

gantenerumab as subcutaneous injection with optimized titration up to the

target dose. The primary endpoint for both trials is the assessment of signs

and symptoms of dementia, measured as the clinical dementia rating-sum of

boxes (CDR-SOB) score, determined as the change of the status from baseline

to week 104.

"This is great news for MorphoSys. We are delighted by the commitment to

gantenerumab as a potential new therapy for Alzheimer's disease, and the

sustained clinical development of this antibody in this area of immense

unmet medical need. We look forward to seeing the effect of the optimized

dosing regimen in the new phase 3 trials run by our partner Roche in early

Alzheimer's patients", commented Dr. Markus Enzelberger, Chief Scientific

Officer of MorphoSys AG.

More information about gantenerumab clinical studies is available on

clinicaltrials.gov. [1]

About MorphoSys

MorphoSys is a late-stage, biopharmaceutical company devoted to the

development of innovative and differentiated therapies for patients

suffering from serious diseases. Based on its technological leadership in

generating antibodies, MorphoSys, together with its partners, has developed

and contributed to the development of more than 100 product candidates, of

which 28 are currently in clinical development. This broad pipeline spans

MorphoSys's two business segments: Proprietary Development, in which

MorphoSys invests in product candidates for its own account, and Partnered

Discovery, in which product candidates are developed exclusively for a

variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab),

marketed by Janssen, became the first therapeutic antibody based on

MorphoSys's proprietary technology to receive marketing approval for the

treatment of moderate to severe plaque psoriasis in the United States, the

European Union and Canada. MorphoSys is listed on the Frankfurt Stock

Exchange and on the U.S. stock exchange Nasdaq, under the symbol MOR. For

regular updates about MorphoSys, visit http://www.morphosys.com [2].

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),

arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio

Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys

Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

_MorphoSys forward looking statements_

This communication contains certain forward-looking statements concerning

the MorphoSys group of companies, including the commencement of the

GRADUATE-trials in connection with gantenerumab and expectations regarding

the development of gantenerumab in Alzheimer's disease, including the

intended targeting of Amyloid-beta. The forward-looking statements contained

herein represent the judgment of MorphoSys as of the date of this release

and involve known and unknown risks and uncertainties, which might cause the

actual results, financial condition and liquidity, performance or

achievements of MorphoSys, or industry results, to be materially different

from any historic or future results, financial conditions and liquidity,

performance or achievements expressed or implied by such forward-looking

statements. In addition, even if MorphoSys' results, performance, financial

condition and liquidity, and the development of the industry in which it

operates are consistent with such forward-looking statements, they may not

be predictive of results or developments in future periods. Among the

factors that may result in differences are the inherent uncertainties

associated with competitive developments, clinical trial and product

development activities and regulatory approval requirements, MorphoSys'

reliance on collaborations with third parties and other risks indicated in

the risk factors included in MorphoSys's Registration Statement on Form F-1

and other filings with the US Securities and Exchange Commission. Given

these uncertainties, the reader is advised not to place any undue reliance

on such forward-looking statements. These forward-looking statements speak

only as of the date of publication of this document. MorphoSys expressly

disclaims any obligation to update any such forward-looking statements in

this document to reflect any change in its expectations with regard thereto

or any change in events, conditions or circumstances on which any such

statement is based or that may affect the likelihood that actual results

will differ from those set forth in the forward-looking statements, unless

specifically required by law or regulation.

*For more information, please contact:*

*MorphoSys AG*

Alexandra Goller

Associate Director Corporate Communications & IR

Jochen Orlowski

Associate Director Corporate Communications & IR

Dr. Claudia Gutjahr-Löser

Investor Relations Officer

*Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com*

Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=FDQWDIKKKN [3]

Document title: Press Release

2018-06-12 Dissemination of a Corporate News, transmitted by DGAP - a

service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,

Financial/Corporate News and Press Releases.

Archive at www.dgap.de

Language: English

Company: MorphoSys AG

Semmelweisstr. 7

82152 Planegg

Germany

Phone: +49 (0)89 899 27-0

Fax: +49 (0)89 899 27-222

E-mail: investors@morphosys.com

Internet: www.morphosys.com

ISIN: DE0006632003

WKN: 663200

Indices: TecDAX

Listed: Regulated Market in Frankfurt (Prime Standard); Regulated

Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich,

Stuttgart, Tradegate Exchange

End of News DGAP News Service

694269 2018-06-12

1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=2f013533eab6f3f8467c2f9874517bd8&application_id=694269&site_id=vwd&application_name=news

2: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=af6b62de1fd30b6c8f4ab4736ef0907c&application_id=694269&site_id=vwd&application_name=news

3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=fba9afcc192a03953deb265adeb5583e&application_id=694269&site_id=vwd&application_name=news

(END) Dow Jones Newswires

June 12, 2018 16:01 ET ( 20:01 GMT)

This news has been published by title PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

If the page you permission is error or not entre perfectly, please visit the native web in source CLICK HERE

Thank you for your visit to our website, hopefully the guidance we convey is useful, complete not forget to allowance and subscribe our web to acquire more information.

[TAG]1354
PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

Source:Finanztreff

PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

Source:4-Traders

PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway

Source:4-Traders

PRESS RELEASE: New Phase 3 Clinical Trials By MorphoSys\'s Partner With Gantenerumab In Early Alzheimer\'s Disease Now Underway